

ADAP Hepatitis C Treatment Coverage

June 2016

Background

NASTAD (the National Alliance of State & Territorial AIDS Directors) continues work to ensure that individuals co-infected with HIV and hepatitis C (HCV) can gain access to curative treatments for HCV via ADAP. NASTAD asked states that have added one or more of the directly-acting antiviral (DAA) HCV treatment medications to complete an online request for information (RFI). The ADAP Hepatitis C Treatment Coverage RFI was produced as part of NASTAD's cooperative agreement with the Health Resources and Services Administration (HRSA).

To date, twenty ADAPs have added one or more of the DAA HCV medications to their formulary; seventeen ADAPs responded to this RFI. **All responses to the RFI were reported as of May 1, 2016.**

Key Findings

ADAP Formulary Inclusion of DAA HCV Medications

Below is a summary of the numbers of ADAPs that cover each of the currently available DAA HCV medications. **To date, 324 ADAP clients have received a DAA HCV prescription via the full-pay prescription program. 283 ADAP clients have received a DAA HCV prescription via the ADAP-funded insurance program.**

ADAP FORMULARY COVERAGE		
DAA HCV Medication	Full-Pay Prescription	ADAP-Funded Insurance
daclatasvir (Daklinza)	10	9
dasabuvir, ombitasvir / paritaprevir / ritonavir (Viekira Pak)	15	12
elbasvir and grazoprevir (Zepatier)	9	9
ledipasvir and sofosbuvir (Harvoni)	16	13
ombitasvir, paritaprevir and ritonavir (Technivie)	10	9
simeprevir (Olysio)	9	11
sofosbuvir (Sovaldi)	15	13

ADAP Formulary Coverage Policies and Restrictions

ADAPs may have additional policies that are used to determine clients' eligibility to receive coverage for a DAA HCV medication. These policies may be determined by the ADAP directly or may be the result of either statewide policy or individual private insurance plan restrictions. The following tables summarize ADAPs' current use of policies to determine DAA HCV medication utilization and coverage under their full-pay prescription and ADAP-funded insurance programs.

ADAP FORMULARY COVERAGE POLICIES		
POLICY	FULL-PAY RX	ADAP-FUNDED INSURANCE
Cap or maximum number of prescriptions/expenditures per client	0	0
Cap or maximum number of clients to receive prescriptions or total expenditures	4	0
Cap or maximum number of clients	N/A	1
Fibrosis score restriction or prioritization (e.g., F3 or F4)	2 ¹	1 ²
Prior authorization	10	4
Proof of denial by other payer (e.g., Medicaid)	6	0
Sobriety requirement	2	1
Specialist provider supervision requirement (e.g., hepatologist)	1	1
No restrictions, open access	2	8

ADAP Utilization of DAA HCV Medications

Full-Pay Prescription Program: 324 clients received a prescription for DAA HCV medication(s) via the ADAP full-pay prescription program as of May 1, 2016. Six ADAPs are able to report on the cure rate among their clients to receive a prescription; 105 clients have been reported cured.

ADAP-Funded Insurance Program: 283 clients received a prescription for DAA HCV medication(s) via the ADAP-funded insurance program as of May 1, 2016. Four ADAPs are able to report on the cure rate among their clients to receive a prescription; 40 clients have been reported as cured.

¹ One ADAP reported that they will restrict or prioritize treatment to individuals with fibrosis scores of F3 or F4. One ADAP reported that they will cover treatment for individuals with F2, F3, or F4.

² One ADAP reported that they will restrict or prioritize treatment to individuals with fibrosis scores of F2, F3, or F4.